Common Contracts
628 similar Underwriting Agreement contracts by Apogee Therapeutics, Inc., Celldex Therapeutics, Inc., Cidara Therapeutics, Inc., others
●] Shares Apogee Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 5th, 2024 • Apogee Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
CELLDEX THERAPEUTICS, INC. 8,520,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • March 1st, 2024 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 8,520,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 8,520,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,278,000 Shares pursuant to such option collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Leerink Partners LLC and Cowen and Company, LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used herein shall mean Le
23,014,000 Shares Iovance Biotherapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 20th, 2024 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
· make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or
17,162,472 Shares of Common Stock Larimar Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 16th, 2024 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • New York
4,325,000 Shares Corbus Pharmaceuticals Holdings, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 1st, 2024 • Corbus Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
Introductory. Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,325,000 shares of its common stock, par value $0.0001 per share (the “Shares”). The 4,325,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 648,750 Shares as provided in Section 2. The additional 648,750 Shares to be sold by the Company are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Securities.”
Alto Neuroscience, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 29th, 2024 • Alto Neuroscience, Inc. • Pharmaceutical preparations • New York
4,615,384 Shares Tourmaline Bio, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 26th, 2024 • Tourmaline Bio, Inc. • Biological products, (no disgnostic substances) • New York
56,700,000 Shares Esperion Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 22nd, 2024 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
Introductory. Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 56,700,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 56,700,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 8,505,000 Shares as provided in Section 2. The additional 8,505,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional under
7,142,858 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 19th, 2024 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • New York
3,168,275 Shares Pre-Funded Warrants to Purchase 1,056,725 Shares Praxis Precision Medicines, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 12th, 2024 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
3,500,000 Shares Keros Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 4th, 2024 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
14,300,000 Common Shares AC IMMUNE SA UNDERWRITING AGREEMENTUnderwriting Agreement • December 19th, 2023 • AC Immune SA • Pharmaceutical preparations • New York
VERU INC. 45,833,333 Shares of Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • December 18th, 2023 • Veru Inc. • Pharmaceutical preparations • New York
Veru Inc., a Wisconsin corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 45,833,333 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”). The 45,833,333 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 6,874,999 Shares, which are called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Raymond James & Associates, Inc. (“Raymond James”) and Oppenheimer & Co. Inc. (“Oppenheimer”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as
3,491,620 Shares Liquidia Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • December 14th, 2023 • Liquidia Corp • Pharmaceutical preparations • New York
Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 3,491,620 shares of its common stock, par value $0.001 per share (the “Shares”). The 3,491,620 Shares to be sold by the Company are called the “Offered Shares.” BofA Securities, Inc. (“BofA”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean you, as Underwriter, and the term “Underwriters” shall mean either the singular or the plural, as the context requires.
30,800,000 Shares Ocular Therapeutix, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 14th, 2023 • Ocular Therapeutix, Inc • Pharmaceutical preparations • New York
BOFA SECURITIES, INC. PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022
20,000,000 Ordinary Shares Wave Life Sciences Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • December 8th, 2023 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
CELLDEX THERAPEUTICS, INC. 7,425,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • November 8th, 2023 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 7,425,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 7,425,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,113,750 Shares pursuant to such option collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Jefferies LLC and Leerink Partners LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used herein shall mean Jefferies L
7,370,690 Shares and Pre-Funded Warrants to Purchase 1,250,000 Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 6th, 2023 • Alx Oncology Holdings Inc • Pharmaceutical preparations • New York
9,669,631 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,121,736 Shares of Common Stock MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 9th, 2023 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • New York
21,000,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • July 13th, 2023 • Savara Inc • Pharmaceutical preparations • New York
20,000,000 Shares Iovance Biotherapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • July 11th, 2023 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
The foregoing will not apply to (i) the registration of the offer and sale of the Shares, and the sale of the Shares to the Underwriters, in each case as contemplated by the Underwriting Agreement, (ii) the exercise of any option, warrant or other right to acquire shares of common stock of the Company, the settlement of any stock-settled stock appreciation rights, restricted stock or restricted stock units, or the conversion of any convertible security into securities of the Company; provided that any securities received as a result thereof by the undersigned will also be subject to the restrictions in this letter agreement, (iii) establishment of a trading plan meeting the requirements of Rule 10b5-1 under the Exchange Act for the transfer of Shares, if then permitted by the Company and applicable law; provided that such plan does not provide for any sales or transfers of Shares during the Lock-up Period, (iv) the transfer of Shares or Related Securities by gift, (v) the transfer of S
●] Shares Apogee Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • July 3rd, 2023 • Apogee Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the Lock-up Period, the undersigned will not (and, if the undersigned is a natural person, will cause any Family Member not to), subject to the exceptions set forth in this letter agreement, without the prior written consent of Jefferies and Cowen, which may withhold their consent in their sole discretion:
1,597,827 Shares of Common Stock 9,000,000 Shares of Non-Voting Common Stock IGM Biosciences, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 23rd, 2023 • IGM Biosciences, Inc. • Pharmaceutical preparations • New York
55,150,000 Shares Pre-Funded Warrants to Purchase 7,050,000 Shares Praxis Precision Medicines, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 20th, 2023 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
VOLITIONRX LIMITED 13,000,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • June 5th, 2023 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 13,000,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 13,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,950,000 Shares (the “Option Shares”). The Firm Shares and, if and to the extent such option or any Underwriter Warrant (as defined below) is exercised, the Option Shares and Underwriter Warrant Shares (as defined below), are collectively called the “Offered Shares.” The Offered Shares and Underwriter Warrants are hereinafter referred to together as the “Securities.” Prime Executions, Inc. dba Freedom Capital Markets (“Freedom”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offerin
OCUGEN, INC. 30,000,000 Shares of Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • May 25th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances) • New York
Ocugen, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 30,000,000 shares of its common stock, par value $0.01 per share (the “Shares”). The 30,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 4,500,000 Shares, which are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean Cantor, as Underwriter, and the term “Underwr
6,875,000 Shares Reneo Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 5th, 2023 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
5,333,334 Shares Morphic Holding, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 3rd, 2023 • Morphic Holding, Inc. • Pharmaceutical preparations • New York
Introductory. Morphic Holding, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,333,334 shares of its common stock, par value $0.0001 per share (“Shares”). The 5,333,334 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 800,000 Shares as provided in Section 2. The additional 800,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC and Cowen and Company, LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional unde
Establishment Labs Holdings Inc. 1,100,000 Common Shares Underwriting AgreementUnderwriting Agreement • April 27th, 2023 • Establishment Labs Holdings Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
4,750,000 Shares TELA Bio, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 20th, 2023 • TELA Bio, Inc. • Surgical & medical instruments & apparatus • New York
5,000,000 Shares Protagonist Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • April 10th, 2023 • Protagonist Therapeutics, Inc • Pharmaceutical preparations • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • March 30th, 2023 • Avadel Pharmaceuticals PLC • Pharmaceutical preparations • New York
The ADSs will be evidenced by American Depositary Receipts (the “ADRs”) to be issued pursuant to a deposit agreement dated as of January 3, 2017 (the “Deposit Agreement”), among the Company, The Bank of New York Mellon, as depositary (the “Depositary”), and the holders from time to time of the ADRs evidencing the ADSs issued thereunder. The Company shall, following subscription by the Underwriters of the Firm ADSs and, if applicable, the Optional ADSs, deposit, on behalf of the Underwriters, the Shares represented by such ADSs with The Bank of New York Mellon, as custodian (the “Depositary Custodian”) for the Depositary, which shall deliver such ADSs to the Representative for the account of the several Underwriters for subsequent delivery to the other several Underwriters or the investors, as the case may be.
9,640,000 Shares Cidara Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 6th, 2023 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
286,000 Shares Cidara Therapeutics, Inc. Series X Preferred Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 6th, 2023 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
ROIVANT SCIENCES LTD. 26,666,666 Common Shares (par value $0.0000000341740141 per share) Underwriting AgreementUnderwriting Agreement • February 7th, 2023 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
Roivant Sciences Ltd., a Bermuda exempted limited company (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 26,666,666 of its common shares, par value $0.0000000341740141 per share (the “Shares”). The 26,666,666 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 3,999,999 Shares as provided in Section 2. The additional 3,999,999 Shares to be sold by the Company pursuant to such option are called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offer
